Sign up to save your podcasts
Or
Share Prostate Cancer Management from Early Stage to Advanced Metastatic Disease - Dr. Alan Bryce
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Prostate Cancer Management from Early Stage to Advanced Metastatic Disease - Dr. Alan Bryce
Join us in this insightful episode of the Oncology Brothers podcast as we dive deep into the current treatment landscape of prostate cancer with Dr. Alan Bryce, Chief Clinical Officer and GU Medical Oncologist from City of Hope.
In this episode, we explore:
• The treatment paradigm for early-stage prostate cancer, including the role of active surveillance and the use of abiraterone based on the STAMPEDE trial.
• The importance of understanding risk factors and treatment options for low, intermediate, and high-risk patients.
• The implications of PET-PSMA imaging versus conventional CT modalities in staging and treatment decisions.
• The management of biochemical recurrent disease and the significance of PSA doubling time in treatment planning.
• The role of PARP inhibitors in patients with HRR mutations and the nuances of selecting appropriate therapies.
• Strategies for managing metastatic disease, including the use of Lutetium-177 (Pluvicto) and cabazitaxel.
Dr. Bryce provides a masterclass on navigating the complexities of prostate cancer treatment, emphasizing the need to balance between over-treatment in early disease and under-treatment in metastatic cases.
YouTube: https://youtu.be/Zfu-yGmH0rg
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
If you find this episode helpful, please share it with your colleagues and leave us a review! Don't forget to check out our other episodes in the GU treatment algorithm series, including discussions on renal cell carcinoma and bladder cancer.
View all episodes
By Oncology Brothers
4.8
4040 ratings
Join us in this insightful episode of the Oncology Brothers podcast as we dive deep into the current treatment landscape of prostate cancer with Dr. Alan Bryce, Chief Clinical Officer and GU Medical Oncologist from City of Hope.
In this episode, we explore:
• The treatment paradigm for early-stage prostate cancer, including the role of active surveillance and the use of abiraterone based on the STAMPEDE trial.
• The importance of understanding risk factors and treatment options for low, intermediate, and high-risk patients.
• The implications of PET-PSMA imaging versus conventional CT modalities in staging and treatment decisions.
• The management of biochemical recurrent disease and the significance of PSA doubling time in treatment planning.
• The role of PARP inhibitors in patients with HRR mutations and the nuances of selecting appropriate therapies.
• Strategies for managing metastatic disease, including the use of Lutetium-177 (Pluvicto) and cabazitaxel.
Dr. Bryce provides a masterclass on navigating the complexities of prostate cancer treatment, emphasizing the need to balance between over-treatment in early disease and under-treatment in metastatic cases.
YouTube: https://youtu.be/Zfu-yGmH0rg
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
If you find this episode helpful, please share it with your colleagues and leave us a review! Don't forget to check out our other episodes in the GU treatment algorithm series, including discussions on renal cell carcinoma and bladder cancer.
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
321 Listeners
Journal of Clinical Oncology (JCO) Podcast
39 Listeners
Research To Practice | Oncology Videos
116 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
290 Listeners
White Coat Investor Podcast
2,430 Listeners
The Curbsiders Internal Medicine Podcast
3,332 Listeners
Core IM | Internal Medicine Podcast
1,140 Listeners
The ONS Podcast
200 Listeners
OncoPharm
184 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
21 Listeners
Becker’s Healthcare Podcast
188 Listeners
Oncology Today with Dr Neil Love
56 Listeners
Two Onc Docs
185 Listeners